The new product pipeline is the most costly and strategically demanding endeavor for research and development-based pharmaceutical and biotech companies.

Substantial R&D investments must be predicated on comprehensive, robust forecasts that can help justify clinical study design in the earliest phases and guide commercial strategy all the way through a successful launch.

This requires dynamic models that anticipate product and market changes. However, pharmaceutical and biotech pipeline forecasts are often based on simplistic templates that incorporate only basic variables such as market research and prescriber preferences when projecting product uptake.  These simplistic models fail to identify, calibrate and incorporate other critical variables that will impact both uptake and revenue including detailed epidemiology assessments, patient persistence and compliance, harmonization across indications and geographies and therapeutic segmentation.

At Viscadia, we design and build sophisticated, dynamic pharmaceutical and biotech pipeline forecast models that give you the highest levels of clarity and confidence – no matter what future timeframe you are looking at.  Working collaboratively with your internal stakeholders, we identify and assemble the most important variables and forecast drivers into a model that is comprehensive, dynamic and clear.

Another benefit of Viscadia’s design philosophy: we build our models to allow seamless transition from the pipeline phase through launch and into on-market application, eliminating the need to develop a separate on-market forecasting tool.